Department of Maternal Fetal Medicine, KK Women's and Children's Hospital, 100 Bukit Timah Road, Singapore, 229899, Singapore.
Department of Obstetrics and Gynaecology, University of Malaya Medical Centre, Lembah Pantai, 59100, Kuala Lumpur, Malaysia.
Arch Gynecol Obstet. 2022 Jan;305(1):11-18. doi: 10.1007/s00404-021-06090-y. Epub 2021 May 11.
To evaluate the safety in the first 12 h, efficacy and maternal satisfaction of a double balloon catheter (DBC) with vaginal prostaglandin (PGE) for induction of labour (IOL).
We conducted a multicentre randomised controlled study of 420 patients from 1st January 2016 to 31st December 2017 to evaluate the use of DBC in IOL in an Asian population looking at the adverse effects in the first 12 h after insertion. Women were assigned randomly to cervical ripening with either a DBC or a prostaglandin pessary. The adverse events in the 12 h after DBC or first prostaglandin inserted, the efficacy of a DBC to a prostaglandin in labour induction and maternal satisfaction were evaluated.
There were significantly less women with uterine hyperstimulation in the DBC (2 vs 24, p ≤ 0.0001) compared to the prostaglandin group. There were no women with uterine hyperstimulation and non-reassuring foetal status in the DBC while there were 5 women with uterine hyperstimulation and foetal distress in the prostaglandin group. Use of entonox was significantly less in the DBC group (p = 0.009). There were no significant differences in both groups in caesarean section, vaginal deliveries and time to delivery, although significant less time was needed to achieve cervical os dilation more than 4 cm in the DBC group (p ≤ 0.0001). Neonatal birth outcomes were similar. Women's pain scores were similar for both methods. 80.1% of women allocated the DBC and 76.8% of women allocated the PGE were keen to recommend their method of induction.
Double balloon catheter remains a good alternative method for inducing women in view of a good safety profile with low risk of hyperstimulation and high maternal satisfaction.
ClinicalTrials.gov Identifier: NCT02620215.
评估双球囊导管(DBC)联合阴道前列腺素(PGE)用于引产(IOL)在最初 12 小时内的安全性、有效性和产妇满意度。
我们进行了一项多中心随机对照研究,纳入了 2016 年 1 月 1 日至 2017 年 12 月 31 日期间的 420 名患者,以评估在亚洲人群中使用 DBC 进行 IOL 的效果,观察插入后最初 12 小时内的不良反应。将患者随机分为宫颈成熟组,分别使用 DBC 或前列腺素栓剂。评估 DBC 或首次插入前列腺素后 12 小时内的不良事件、DBC 与前列腺素在引产中的效果以及产妇满意度。
DBC 组的子宫过度刺激发生率明显低于前列腺素组(2 例 vs 24 例,p≤0.0001)。DBC 组无一例出现子宫过度刺激和胎儿情况不稳定,而前列腺素组有 5 例出现子宫过度刺激和胎儿窘迫。DBC 组使用恩诺酮的比例明显较低(p=0.009)。两组在剖宫产、阴道分娩和分娩时间方面无显著差异,尽管 DBC 组达到宫颈口扩张超过 4cm 所需的时间明显缩短(p≤0.0001)。新生儿出生结局相似。两种方法的产妇疼痛评分相似。80.1%的接受 DBC 治疗的产妇和 76.8%的接受前列腺素治疗的产妇愿意推荐其引产方法。
鉴于 DBC 具有良好的安全性,子宫过度刺激风险低,产妇满意度高,DBC 仍然是一种很好的替代引产方法。
ClinicalTrials.gov 标识符:NCT02620215。